Ewing's sarcoma
ICD-10 C40 · ICD-11 2B52

First-line treatment of Ewing's sarcoma: compressed-interval chemotherapy and local control

Clinical Scenario

Ewing's sarcoma is an aggressive primary bone tumour requiring combined systemic and local treatment from the outset. First-line management is initiated promptly, with chemotherapy response guiding local treatment decisions for the primary tumour.

Treatment Approach

The preferred first-line strategy involves compressed-interval combination chemotherapy, integrated with definitive local treatment of the primary tumour — surgical resection and/or radiotherapy — depending on tumour characteristics, anatomical location, and patient fitness.

Full regimen details, drug schedule, cycle count, and local treatment decision criteria are in the structured protocol below.

Key Treatment Goals
Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1038/s41416-024-02868-4

Greater treatment intensity is linked to better outcomes: a two-weekly interval-compressed VCD/IE induction was demonstrated to be more effective than the same regimen given three-weekly and VDC/IE induction followed by IE/VC consolidation has better outcomes than VIDE induction and VAI or VAC consolidation and is now the preferred first-line treatment for all patients who are medically fit to receive it.

Complete removal of the primary tumour (meaning the parts of all anatomical structures involved in the original tumour volume) provides optimal local control but is not always feasible, for example, because critical anatomical structures are involved.

Radiotherapy should be considered in addition to surgery if there is a poor radiological or histological response to chemotherapy, the surgical margins are inadequate, the tumour is large or is in a high-risk area (e.g. pelvis).

Definitive radiotherapy is frequently recommended for tumours judged to be inoperable, those in anatomic locations where complete removal would cause unacceptable morbidity (e.g. pelvic and sacral tumours), in patients at unacceptable risk of significant surgical complications, and if the prognosis is poor (e.g. widespread bone metastases) such that morbidity of surgery is not appropriate.

If there is a poor histological response (≤90% necrosis) to pre-operative chemotherapy, even if the resection margins are negative.

Tumour volume change can be seen on MRI, and reliably reflects chemotherapy response particularly if late.

View source ↗